New AbbVie Collaboration Shows Two-Pillar Strategy Working For Halozyme
This article was originally published in The Pink Sheet Daily
Executive Summary
The San Diego biotech reported promising interim Phase II data for its lead cancer program at ASCO, while announcing an ENHANZE platform deal with AbbVie and companion diagnostic tie-up with Ventana.